MSCopilot Detect emerges as early contender for scalable remote MS monitoring, says GlobalData
From the article
Digital biomarkers are gaining momentum in multiple sclerosis (MS) care, with new findings highlighting the potential of smartphone-based assessments to transform disability monitoring. Early evidence supporting MSCopilot Detect use underscores growing industry efforts to enable scalable, remote, and standardized disease assessment, a shift that could reshape clinical patient monitoring, and the evaluation of MS disease […]
Continue reading on globaldata.comYou might also wanna read

STAT+: In private meeting, Trump officials push to onshore generic drugmaking
STAT·9h ago

FDA-awarded RMAT designations continue to surge in 2025, reveals GlobalData
globaldata.com·22h ago

Europe–US new drug manufacturing outsourcing gap widens, reveals GlobalData
globaldata.com·2d ago
Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData
globaldata.com·5d ago
Produodopa’s positive RWE for Parkinson’s disease to boost clinician confidence in crowded levodopa market, says GlobalData
globaldata.com·7d ago
EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData
globaldata.com·7d ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.